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Abstract
Background: Insufficient migration and activation of tumor specific effector T cells in the tumor is one of the main
reasons for inadequate host anti-tumor immune response. External radiation seems to induce inflammation and
activate the immune response. This phase I/II clinical trial aims to evaluate whether low dose single fraction
radiotherapy can improve T cell associated antitumor immune response in patients with colorectal liver metastases.
Methods/Design: This is an investigator-initiated, prospective randomised, 4-armed, controlled Phase I/II trial.
Patients undergoing elective hepatic resection due to colorectal cancer liver metastasis will be enrolled in the
study. Patients will receive 0 Gy, 0.5 Gy, 2 Gy or 5 Gy radiation targeted to their liver metastasis. Radiation will be
applied by external beam radiotherapy using a 6 MV linear accelerator (Linac) with intensity modulated
radiotherapy (IMRT) technique two days prior to surgical resection. All patients admitted to the Department of
General-, Visceral-, and Transplantion Surgery, University of Heidelberg for elective hepatic resection are
consecutively screened for eligibility into this trial, and written informed consent is obtained before inclusion. The
primary objective is to assess the effect of active local external beam radiation dose on, tumor infiltrating T cells as
a surrogate parameter for antitumor activity. Secondary objectives include radiogenic treatment toxicity,
postoperative morbidity and mortality, local tumor control and recurrence patterns, survival and quality of life.
Furthermore, frequencies of systemic tumor reactive T cells in blood and bone marrow will be correlated with
clinical outcome.
Discussion: This is a randomized controlled patient blinded trial to assess the safety and efficiency of low dose
radiotherapy on metastasis infiltrating T cells and thus potentially enhance the antitumor immune response.
Trial registration: ClinicalTrials.gov: NCT01191632
Keywords: colorectal liver metastasis, low dose radiation, tumor specific T cells
Background
Colorectal cancer (CRC) is the most frequent cancer in
the western world [1]. Advanced tumor stage with
metastasis is one of the main reasons for the high mor-
tality rate. At the time of diagnosis, approximately 30%
of patients have distant metastases which predominantly
occur in the liver. Surgical removal of the tumor still
remains the only curative approach [2,3]. In recent years
survival rates in colorectal cancer have been further
improved because of multimodal therapy concepts, espe-
cially in UICC stage III and IV patients. In parallel to
these modern multimodal therapy concepts, novel and
promising concepts including immunotherapeutic
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improve clinical outcome.
Most patients with CRC have high numbers of tumor
specific T cells (cytotoxic T cells and T helper cells) in
their blood and bone marrow [4,5]. The molecular iden-
tification of tumor-associated antigens (TAA) has led to
the development of antigen-specific immunotherapy tar-
geting these antigens. To the present these strategies
have failed to show efficacy in clinical practice. Potential
reasons for this lack of efficacy include the inefficiency
of T cell activation in vivo, insufficient migration of
cytotoxic T cells into the tumor, the choice of irrelevant
antigens, induction or application of monovalent T cells
or the treatment of patients in highly advanced tumor
stages [6]. In particular inadequate T cell infiltration,
characterized by selective recruitment of immune sup-
pressive regulatory T cells as well as insufficient immi-
gration of cytotoxic T cells [7-9] appears to be a serious
hurdle, partially explainable by poorly activated endothe-
lium of the tumor vessels [10]. Furthermore, the cyto-
toxic and secretory activity of tumor specific T cells
m a yb ei n h i b i t e db yt h ei m m u n o s u p p r e s s i v ee n v i r o n -
ment of the tumor stroma after immigration into the
tumor.
Ionizing radiation therapy (RT) is an effective local
cancer therapy, which kills cancer and other cells within
the tumor stroma, including endothelial cells and intra-
tumoral lymphocytes [11]. RT typically induces primar-
ily mitotic cell death but also leads to apoptosis [12].
Radiation has also complex effects on the tumor micro-
environment and microvessels, which can facilitate the
homing of both antigen presenting and effector T cells
to the tumor [10,13].
T u m o rc e l l sk i l l e db yR Tm a yb eag o o ds o u r c eo f
antigens for Dendritic Cell (DC) uptake and presenta-
tion to T cells. DCs are attracted by the altered micro-
environment and undergo maturation after internalizing
the debris. These dendritic cells can then present tumor
specific antigens to T-cells following the processing of
debris [14]. The possibility of using RT to promote
tumor antigen-presentation by DC has been explored.
Sublethal doses of ionising radiation have been
described to enhance antitumor T-cell activity in such
indirect ways in animal studies. Radiation has also been
described to directly lead to an amplification of expres-
sion of MHC. This can render tumor cells more sensi-
tive to the detection and lysis by specific T-cells [15].
Furthermore ionizing radiation can lead to activated
endothelium thus facilitating the immigration of T-cells
into the tumor. Overall, the available preclinical in vivo
data support the hypothesis that RT may provide at
least some of the necessary maturation signals.
So far, no systematic clinical analysis has been per-
formed to investigate the immune stimulatory effects of
low dose radiotherapy in patients with CRC. One issue
to be addressed is the effective radiation dose to act as a
form of immunotherapy. In fact, scant data are available
with regard to the specific radiosensitivity of the differ-
ent cellular components of the immune system. Studies
describing the effects of RT on circulating immune cells
are also lacking along with data on radiation effects on
the microenvironment.
We here present the protocol of a clinical phase I/II
trial with the aim to determine the active local external
beam radiation dose resulting in tumor infiltrating T
cells in patients with liver metastasis from CRC. The
liver metastases will be irradiated two days prior to sur-
gery using external beam radiotherapy. As primary end-
points we will determine the active local radiation dose
leading to metastasis infiltrating T cells as a surrogate
parameter for antitumor activity. Secondary objectives
include local tumor control, survival, treatment toxicity
as well as quality of life. Furthermore, blood cell tran-
scriptomics and plasma-proteomics will be correlated
with the amount of tumor reactive T cells in blood and
bone marrow.
Methods/Design
Trial population and patient recruitment
This trial focuses on patients with resectable liver
metastases of CRC. Patients scheduled for elective hepa-
tic resection due to colorectal liver metastasis will be
enrolled in this study. Only patients over 50 years of age
are allowed to participate in this study due to the radia-
tion protection law. Based on the preoperative imaging
the surgeon determines if the liver metastasis can be
resected in curative intent. Patients with unresectable
liver metastasis, secondary malignancies, liver cirrhosis
or previous radiotherapy to the upper abdomen will be
excluded from the trial (see Table 1).
Patients who meet the eligibility criteria and provide
written informed consent are randomly allocated to
either study intervention to balance treatment groups
Table 1 Eligibility criteria
Inclusion criteria
Liver metastasis of colorectal cancer
Metastasis is curatively resectable
Written informed consent of the patient
No evidence of active or former concurrent malignant diseases
Exclusion criteria
Previous radiotherapy to the upper abdomen
Participation in other therapeutical trials
Liver cirrhosis
Pregnancy
No willingness on regular follow up care
Any extrahepatic disease
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tors. A block randomisation list is created via a compu-
ter system. Patients are randomised using consecutively
numbered opaque envelopes prepared and sealed by an
independent study nurse. The envelopes will be opened
sequentially only after the participant’sn a m ei sw r i t t e n
on the appropriate envelope. Neither the screening
investigators nor the investigators who inform the
potential participants about this trial and enrolling the
patients, have any knowledge of the block randomisation
list or the previous allocations to treatment. There is no
stratification for randomisation.
After informed consent, patients are randomized
either to the control group - receiving no radiation - or
the three irradiation treatment groups. Within the irra-
diation treatment groups patients will receive 0.5 Gy, 2
Gy or 5 Gy single fraction radiation 48 h prior to resec-
tion. After the adjustment of an individual positioning
device, computed tomography and, if needed, magnetic
resonance imaging (MRI) treatment planning examina-
tions are performed. After 3D inverse treatment plan-
ning and plan optimizing using VIRTUOS and
KONRAD software, intensity modulated radiation ther-
apy will be administered using five to nine 6 MV linear
acceleration (LINAC) photon beams. Immediately prior
to the irradiation the setup error of the patient will be
determined via In-Room-CT, and corrected if necessary.
The first blood sample will be obtained (54 ml) before
radiation, a second just prior to the start of the operation.
A bilateral bone marrow sample (27 ml each) will be
taken from both iliac crests after induction of general
anaesthesia just before skin incision. Bone marrow sam-
pling is optional for the patient. EDTA will be used as
anticoagulant for bone marrow and blood samples. After
hepatic resection a part of the tumor will be immediately
removed and stored at -80°C for further analyses.
On the postoperative day seven and at the follow-up/
restaging visits (4 weeks postoperatively, four and seven
months postoperatively) additional venous blood sam-
ples (54 ml) will be obtained. Quality of Life will be
tested using the EORTC QLQ C-30 at four months and
seven months postoperatively. Clinical examination will
be performed and blood samples will be obtained by the
investigators at all visits.
Curative surgery requires complete resection of all
liver metastases, regardless of size, number, distribution,
or width of resection margin. Liver operation will be
carried out under low central venous pressure using a
Péan clamp, ultrasonic dissector or vascular stapler. An
intraoperative ultrasound of the liver will be performed
in all patients to assess the relationship of the lesions to
major vessels and to rule out additional lesions. The
Brisbane 2000 terminology of hepatic anatomy and
resections will be applied [16].
Safety aspects and adverse events
As the radiation dose is relatively low, very few side
effects are expected. Potential adverse events (AE)
include skin alterations like redness, temporary elevated
transaminases, transient nausea or diarrhea. All possible
AEs will be assessed by the RTOG Scale. These AEs
rarely occur in conventional radiotherapy using consid-
erably higher doses (neoadjuvant 5 × 5 Gy for rectal or
gastric cancer, 54 Gy in pancreatic cancer) [17,18].
Study design
This single fraction radiation on colorectal liver metas-
tases trial is a registered (ClinicalTrials.gov -
NCT01191632), investigator-initiated, prospective, ran-
domized controlled phase I/II trial to evaluate the opti-
mal neoadjuvant, single fraction radiation dose for
patients undergoing resection for colorectal liver metas-
tases in curative intent. Patients will be randomised
either to the control group -receiving no radiation- or
the three treatment groups - receiving 0.5 Gy, 2 Gy or 5
Gy single fraction radiation to the metastasis 48 h prior
to the operation. The treatment is offered to a heteroge-
neous group of patient of both sexes, covering a wide
range of comorbidities. For the irradiation a highly con-
formal dose distribution to the tumor with 1 cm safety
margin is delivered using a 6 MV LINAC and intensity
modulated radiotherapy (IMRT) treatment application.
After inclusion of 20 patients an interims analysis will
be performed. The final analysis will be performed
within three month of the inclusion of the last patient.
T h et r i a ld e s i g nw i l ln o tb ec h a n g e dw i t h o u tp r i o r
agreement of the ethics committee.
Translational studies will be carried out by the
Department of Translational Immunology of dkfz, the
Radiation Oncology Departments of German Cancer
Research Center (DKFZ) and the Surgery Departments
of the University Hospital. This trial is an investigator-
initiated trial and is coordinated by the Department of
General-, Visceral- and Transplantation Surgery and the
Radiation Oncology Department of DKFZ. The Radia-
tion Oncology Department of DKFZ is responsible for
the overall trial management, trial registration, database
management, quality assurance including monitoring
and scientific program of all trial related meetings. The
methods and the study design of this trial have the
same structure as the previously published study proto-
col for patients with pancreatic cancer (BMC Cancer
2011; 11:34) [19].
Ethical and legal considerations
The final clinical trial protocol, the patient information
and informed consent sheets were approved by the inde-
pendent ethics committee of the University of Heidel-
berg S081/2008 (http://klinikum.uni-heidelberg.de).
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Page 3 of 6Furthermore, the study has been approved by the Ger-
man Federal Authorities for Radiation Protection (Bun-
desamt fuer Strahlenschutz, Salzgitter, Trial Number
Z5-22461/2-2009-002). Written informed consent is
obtained from each patient in oral and written form
before inclusion in the study. In addition, the protocol
has been reviewed and funded by a scientific third party
funding (grants from Nationales Centrum fuer Tumor-
erkrankungen (NCT)/Tumorzentrum Heidelberg and
Kompetenzverbund Strahlenforschung (KVSF,
03NUK004A,C) of Bundesministerien fuer Bildung, For-
s c h u n gu n dU m w e l t( B M B F / B M U ) ) .P a t i e n t sa r e
informed about the strict confidentiality of their perso-
nal data within this trial, but their pseudonymised medi-
cal records may be reviewed for trial purposes by
authorized individuals other than their treating
physician.
It has to be pointed out that the participation is
voluntary and that the patient is allowed to refuse
further participation in the protocol to any time point
within the study. This trial is carried out in accordance
to the current Declaration of Helsinki (sixth revision,
2008), the principles of “Good Clinical Practice” (GCP),
and the Federal Data Protection Act. It is registered at
the Clinical-Trials.gov protocol registration system
(http://www.clinicaltrials.gov) and the assigned identifi-
cation number is NCT01191632.
Objective of the study
The primary objective of this trial is the determination of
the single fraction radiation dose, measured by the num-
ber of tumor infiltrating T-cells in the tumor. Secondary
molecular objectives are the T cell activity in the resected
tumor specimen, the density of regulatory T cells, and
the frequency of tumor reactive T cells in blood and
bone marrow in correlation with changes in the level of
proteins involved in immune response or angiogenesis
and transcriptomics in whole blood cells. Further clinical
secondary objectives are acute radiogenic toxicity, post-
operative morbidity and mortality, local control, recur-
rence patterns, overall survival and quality of life. All
clinical secondary objectives are presented in Table 2.
Currently, 35 patients are randomized. The duration
of the trial is expected to last four more months.
Usually, two patients per month can be enrolled into
this study. Evaluation and reporting of the clinical and
laboratory results will be done within three months after
the end of recruitment and closing of the database.
Statistical analysis
This randomized controlled trial is planned as a com-
parison of four parallel groups:
Group 1: Dose = 0 Gy (control); Group 2: Dose = 0.5
Gy; Group 3: Dose = 2 Gy and Group 4: Dose = 5 Gy.
Aim of the study is to determine the maximum active
radiation dose with three different doses. This will be
carried out hierarchically in two consecutive steps.
1. Step: Comparison of the three doses against the
control group ("Many-to-one” comparison after Dunnet)
2. Step: Comparison of the three doses among each
other ("all-subset” comparison)
Each of the two steps happens on multiple levels of
significance with a p-value less than 0.05. The power of
each step should be at least 80%.
Based on achieved information of a study by Galon et
al. [20] in CRC patients, the density of tumor infiltrating
T cells is a relevant prognostic parameter. Patients with
a good prognosis had a mean of x-good = 600 CD8 T
cells/mm
2, the group with a bad prognosis had a mean
of x-bad = 370 CD8 T cells/mm
2. The standard devia-
tion in both groups was 50/mm
2. Further analysis
revealed that patients with x = 300 tumor infiltrating
CD8 T-cells/mm
2 in tumor tissue had a significantly
better prognosis. Given this background, a clinical rele-
vant difference between 100 and 200 CD8 T-cells/mm
2
seems plausible. The number of cases should be suffi-
cient for a difference of 150 CD8 T-cells/mm
2.
For the first step, 32 analyzable patients will be needed
which equals eight patients for each of the four groups.
The nominal power of ANOVA is around 90%. For the
second step (comparison of the best group, Hsu 2006),
the power for n = 32 is 95%. Not all of the randomized
patients could be analyzed with respect to the primary
objective. A failure of 10 - 15% has to be assumed due
to poor tissue quality or technical problems. Therefore,
40 patients should be randomized.
The calculated number of cases was carried out with
PASS 2005 (Hintze J, 2004): NCSS and PASS. Number
Cruncher Statistical Systems. Kaysville, Utah. http://
www.ncss.com) with the procedure for multiple compar-
isons by Jason C. Hsu (1996) (Multiple Comparisons:
Theory and methods, Chapman & Hall). The analysis of
the primary objective results confirmatory on a multiple
level of significance of p < 0.05 by ANOVA based on
the calculated numbers of cases. The analysis of the sec-
ondary objective results is descriptive by determining
the means, the quartiles as location parameter and the
standard deviation and range as dispersion parameters.
Table 2 Secondary endpoints
Secondary endpoints
￿ Local control and recurrence patterns of colorectal liver metastasis
￿ Progression free survival
￿ Surgical morbidity in patients undergoing liver resection who received
this protocol treatment
￿ 30 day postoperative mortality
￿ Radiation toxicity
￿ Quality of life according to EORTC QoL questionnaire after 3 and 6
months
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fied by the Pearson or Spearman test. The EORTC
QLY-C30 single-item and multi-item subscales will be
scored and linearly transformed according to algorithms
recommended by the EORTC. Using two-sample t-tests
for continuous and Pearsons’sX
2 Test for categorical
variables, the intervention and the control arms will be
compared in terms of clinical characteristics at time of
randomisation and in terms of baseline QOL scores.
Repeated measures ANOVA will be applied to test for
changes in the continuous secondary endpoints - e.g.
plasma cytokine levels- as a function of treatment arms.
Follow up
A routine follow up for cancer patients will be done
including physical examination of the patients, tumor
markers (CEA), CT/MRI, chest X-ray every three
months. Disease-free survival and overall survival will be
recorded. Notably, the further clinical management and
postoperative treatment of the patients will not be influ-
enced by the results of this study. The decision whether
patients will receive an adjuvant treatment (e.g. che-
motherapy) is left to the discretion of the treating
oncologist.
Data management and quality assurance
The coordination of this trial lies by the Department of
Surgery and the Radiation Oncology Department of the
German Cancer Research Center (DKFZ). Data regard-
ing T cell detection in blood and bone marrow of all
patients will be entered in a password-protected data-
base at the Department of General-, Visceral- and
Transplantation Surgery, University of Heidelberg and at
the German Cancer Research Center. The clinical data
of all included patients will be centrally collected in a
database located at the Department of Radiation Oncol-
ogy at dkfz. The clinical and laboratory data will be
merged in the password-protected database at the
Department of General-, Visceral- and Transplantation
Surgery, University of Heidelberg, Germany and at the
DKFZ.
Discussion
The primary objective of this clinical phase I/II study is
to investigate if tumor conformal low dose external
beam radiation using 6 MV photons will lead to an
increased number of tumor infiltrating T cells at two
days after irradiation in resectable liver metastases of
colorectal cancer.
The efficient radiotherapeutic treatment of colorectal
liver metastasis is still a challenging task. Eradicating
radiation doses are only applicable for small colorectal
liver metastases because of the high radiation toxicity to
the liver [21]. Therefore, the development of new
therapeutic strategies is required. Cellular immunother-
apy is a promising complimentary tumor treatment
principle. Although the ability of tumor rejection of
tumor specific T lymphocytes is well documented
[22,23], the effectiveness of this approach could not be
translated into clinical trials. It appears to be essential,
that the tumor context has to be specifically modulated
to raise the efficiency for immunotherapy.
Low dose ionizing radiation offers the possibility of a
selective induction of a proinflammatory milieu. In
contrast to systemic adjuvants, a localized synergistic
tumor effect is possible by causing a release of tumor
antigens from necrotic tumor cells and depletion of
regulatory T cells [24]. Ionizing radiation was initially
considered as an immune-suppressive treatment mod-
ality [25], but it has also revealed its potential to
enhance immunity.
Therefore, the hypothesis for the current study was
that an improved T cell infiltration and activation in the
tumor as well as a superior systemic T cell immunity
against tumor antigens can be induced by low dose
radiation therapy. However, the role of radiation as an
independent immune-enhancer is still under investiga-
tion. While encouraging preclinical data are now avail-
able, their translation to the clinic - alone or in
combination with other forms of immune therapy - is
just beginning.
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